IMCD has signed an agreement to acquire Daoqin, a Chinese distributor of functional nutrition, food, and nutraceutical ingredients.
Daoqin, with ~$17.08 million revenue in 2023, will strengthen IMCD’s presence in China’s life sciences market.
Both companies highlight strong synergies and technical expertise, with the deal expected to close in Q2 2025.
